Validation of Doripenem Dosing in Patients with End-Stage Renal Disease Receiving Hemodialysis

Product information. Doribax (doripenem for injection). Titusville, NJ: Ortho-McNeil Pharmaceuticals, Inc., October 2007.

Cirillo I , Redman R , Vaccaro N . Pharmacokinetics of doripenem in subjects with varying degrees of renal impairment. Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the 46th Annual Meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.

Floren L , Wikler M , Kilfoil T , Ge Y. A phase 1 open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously to subjects with renal impairment. Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004.

Tanoue K , Nishi K , Kadowaki D , Hirata S. Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis. Ther Apher Dial 2011;15:327–33.

Craig WA . Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1–12.

Fritsche TR , Stilwell MG , Jones RN . Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005;11:974–84.